Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the fully humanised immunoglobulin G4…
Dermatology
-
-
FDA approves Galderma’s Nemluvio to treat atopic dermatitis
The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for individuals aged 12 years and…
-
AbbVie to acquire Nimble Therapeutics for $200m
AbbVie has agreed to acquire Nimble Therapeutics for $200m in cash at closing, subject to standard adjustments, alongside potential interim…
-
LEO Pharma’s eczema cream gains MHRA marketing authorisation
LEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus…
-
J&J’s sBLAs seek FDA approval of TREMFYA for paediatric conditions
Johnson & Johnson (J&J) has sought approval for TREMFYA (guselkumab) for paediatric conditions with the submission of two supplemental biologics licence…
-
UQ secures funds for development of skin cancer prevention cream
A research team at Australia's University of Queensland (UQ) has secured a A$344,000 grant from the National Foundation for Medical…
-
Aclaris Therapeutics secures global rights to Biosion’s antibodies
Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and BSI-502,…
-
Dermavant acquisition expands Organon’s dermatology portfolio
Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio. With the deal's closure,…
-
Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis
Arcutis Biotherapeutics' subsidiary, Arcutis Canada, has received Health Canada's approval for ZORYVE (roflumilast) topical foam 0.3%, to treat seborrheic dermatitis…
-
LEO Pharma announces Enstilar NDA submission for plaque psoriasis in China
LEO Pharma has submitted a New Drug Application (NDA) to China's National Medical Products Administration for Enstilar, targeting the treatment…
